Alcoholism and Naltrexone

David W. Oslin, MD
Associate Professor
University of Pennsylvania, School of Medicine
And
Philadelphia, VAMC

Hazelden Research Co-Chair on Late Life Addictions

Question # 1

- True or False: The annual cost for the consequences of alcoholism in the US exceeds the annual cost of the Iraq war.

Question # 2

Which of the following diseases requires a lifestyle change for adequate treatment:

1. Diabetes
2. Heart disease
3. Alcoholism
4. Arthritis
5. All of the above

Question # 3

Naltrexone

1. Is a mu opioid receptor agonist
2. Reduces heavy drinking days more than placebo
3. Has a long acting injectable formulation that is free of serious side effects
4. Works best in patients who drink to self-medicate stress or mood symptoms
5. Works least well in familial forms of alcoholism

Question # 4

The opioid receptor gene has alleles that

1. Are associated with increased pain sensitivity
2. Are associated with a greater likelihood of intoxication after drinking a given amount of alcohol
3. When present in alcoholics are associated with response to naltrexone
4. 1, 2, and 3 are correct

Lecture Outline

- General review of diagnosis and impact of alcoholism
- Opioid antagonists and alcoholism – basic science
- Efficacy of naltrexone and depot naltrexone
- Genetics of the mu-opioid receptor and alleles
- Genetic influences on naltrexone efficacy
- Conclusions

Introduction

- Alcoholism costs the nation $150 Billion / annum in the US. As such it is the most expensive addictive disorder.
- Alcoholism leads to increased mortality and morbidity
- Alcoholism is common with about 7 million Americans afflicted
- Worldwide alcoholism is the 7th leading cause of disability

Alcohol Use


Abstinence
Moderate Use
Binge Use
Problems / Abusive Drinking
Dependent

Undertreatment of Alcohol Use Disorders



Defining Alcohol Dependence

- a person's maladaptive pattern of alcohol use leads to clinically important distress or impairment
- 3 of the following in a 12-month period
  - Tolerance
  - Withdrawal
  - More time or larger amounts than desired
  - Desire or effort to cut down
  - Time spent obtaining or recovering
  - Social, occupational or recreational effects
  - Drinking despite consequences

Alcoholism: A Chronic Disease

Alcoholism is often compared to traditional illnesses

Asthma, diabetes, heart disease and arthritis

- Progressive, relapsing disease
- Genetic factors are important
- Symptoms show with advanced disease
- Treatment requires lifestyle changes

What Are the Terms?

Social/Moderate Drinker

- Generally defined as drinking no more than 2 drinks per day
  - No binge drinking
  - Modified for women (1 drinks per day)
  - Modified for older adults (1 drinks per day)

What is a Drink?



Factors Modifying the Ethanol Elimination Rate

- There is a 3-4 fold variability in the rate of ethanol elimination by humans because of genetic and environmental factors, including
  - Sex / genetic factors
  - Age
  - Race
  - Food
  - biological rhythms
  - Exercise
  - Alcoholism
  - Drugs / medications

Know Your State's Consumption

U.S. Total = 2.18



Clinical Components

- Withdrawal (acute and subacute)
- Tolerance
- Social devastation
- Medical consequences
  - CNS – depression, cognition
  - Non-CNS – liver, heart, renal, PNS, pancreas, etc

Risks vs. Benefits

	Risks	Benefits
Abstinence	▪Cardiovascular	▪Social
Moderate	▪Medication interactions	▪Social ▪Cardiovascular
At-Risk	▪Psychological distress ▪Suicide risk ▪Fractures ▪Adherence	▪Social
Abuse	▪Social ▪Legal	▪None
Dependence	▪All aspects of health / functioning	▪None

Barriers to Recognition and Treatment

- Patient factors
- Health professional factors
- Healthcare system factors
- Society factors
- Treatment factors

Treatment Options

- Brief therapies
- Self-help groups (AA, ACOA, etc.)
- Individual therapy
- Family therapy
- Psychoeducational activities
- Hypnosis
- Activities therapy
- Group therapy (elder specific)
- Psychopharmacology

Caveats About Treatment

- Addiction treatment is not one size fits all. There are many options—use them
- Compliance with treatment is important. Continually support treatment
- Treatment is not a "carve out" available only in select settings
- While abstinence is often the goal, it is not the only goal

How does Alcohol work at the cellular level?

- Older hypotheses suggesting that ethanol has very generalized, non-specific actions on many neuronal systems seem unlikely
- At intoxicating concentrations, ethanol has some very specific actions on a number of membrane proteins
- Certain kinds of ligand-gated ion channels (i.e., postsynaptic receptors) appear to be an important target for ethanol action
- Experimental strategies need to be developed to determine which actions of ethanol are relevant to specific behavioral effects

Opioid antagonists - basic science



Embellished from Gianoulakis 1998

- Alcohol consumption affects the production, release, and activity of opioid peptides (Herz, 1997)
- Opioid peptides mediate some of alcohol's rewarding effects by enhancing midbrain dopamine release
- Opioid antagonists suppress alcohol-induced reward (Swift,1999) and general consummatory behaviors (Boyle et al. 1998)
- Genetic high-risk / FH+ individuals have an exaggerated alcohol-induced rise in β-endorphin level, and are more responsive to naltrexone treatment (Gianoulakis et al. 1996; King et al. 1997)

Naltrexone

- Functions as an opioid receptor antagonist (mu >> delta or kappa)
- Development was an example of bench to bedside translational science (opioid effects on reward pathways)

Randomized Placebo Controlled Naltrexone Trials

Studies supporting efficacy			Studies not supporting efficacy		
Study	# Ss	Notes	Study	# Ss	Notes
Volpicelli et al 1992	70	None	Oslin et al 1997	44	Older
O'Malley et al 1992	97	None	Kranzler et al 2000	183	None
Volpicelli et al 1997	97	None	Krystal et al 2001	627	VA only
Kranzler et al 1998	20	Depot	Lee et al 2001 (Singapore)	53	None
Anton et al 1999	131	None	Gastpar et al 2002 (Germ.)	171	None
Chick et al 2000 (UK)	169	Adherence	Kranzler et al 2004	315	Depot
Monterosso et al 2001	183	None	Killeen et al 2004	145	None
Morris et al 2001 (Australia)	111	None	Oslin et al in press	240	None
Heinala et al 2001 (Finland)	121	Nonabst.			
Latt et al 2002 (Australia)	107	None			
Ahmadi and Ahmadi 2002 (Iran)	116	None			
Guardia et al 2002 (Spain)	202	None			
Balldin 2003	118	None			
Kiefer et al 2003 (Germany)	160	None			
Kranzler et al 2003	153	None			
Kranzler et al 2004	315	For drinking not relapse			
Anton et al 2004	270	None			

Naltrexone in the Treatment of Alcohol Dependence



Volpicelli et al, *Arch Gen Psychiatry*, 1992; 49: 876-880